Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors

Journal of the American College of Cardiology

Volumn 41, Issue 5, 2003, Pages 718-724

  Freeman, Rosario V ^a   Mehta, Rajendra H ^b   Al Badr, Wisam ^b   Cooper, Jeanna V ^b   Kline Rogers, Eva ^b   Eagle, Kim A ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CREATININE CLEARANCE; DRUG EFFECT; DRUG USE; FEMALE; HEART MUSCLE ISCHEMIA; HOSPITAL PATIENT; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK FACTOR;

EID: 0037420072     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02956-X     Document Type: Article

References (54)

1. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339:799-805.
2. Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002;13:745-53.
3. Shlipak MG, Simon JA, Grady D, et al., for the Heart and Estrogen/progestin Replacement Study (HERS) Investigators. Renal insufficiency and cardiovascular events in postmenupausal women with coronary artery disease. J Am Coll Cardiol 2001;38:705-11.
4. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-9.
5. Aronow WS. Usefulness of serum creatinine as a marker for coronary-events in elderly patients with either systemic hypertension or diabetes mellitus. Am J Cardiol 1991;68:678-9.
6. McCullough PA, Soman SS, Shah SS, et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000;36:679-84.
7. Beattie JN, Soman SS, Sandberg KR, et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 2001;37:1191-200.
8. Furberg CD, Byington RP. What do subgroup analyses reveal about differential response to beta blocker therapy? The Beta Blocker Heart Attack Trial experience. Circulation 1983;67 Suppl I:198-101.
9. Wannamethee SG, Shaper G, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease. Stroke 1997;28:557-63.
10. Krumholz HM, Chen J, Wang Y, Radford MJ, Chen YT, Marciniak TA. Comparing AMI mortality among hospitals in patients 65 years of age and older. Evaluating methods of risk adjustment. Circulation 1999;99:2986-92.
11. Matts JP, Karnegis JN, Campos CT, Fitch LL, Johnson JW, Buchwald H. Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. J Family Prac 1993;36:497-503.
12. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and impact of ramapril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.
13. Pahor M, Short RI, Somes GW, et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Arch Intern Med 1998;158:1340-5.
14. Sabatine M, Jang I. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Am J Med 2000;109:224-37.
15. Harrington RA. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes. Am Heart J 1999;138:S276-86.
16. Eptifibatide. Prescribing Information. COR Therapeutics, Inc.
17. Tirofiban. Prescribing Information. Merck and Co., Inc.
18. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary. Syndromes Writing Committee). J Am Coll Cardiol 2001;38:2114-30.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
20. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39 Suppl 2:S1-246.
21. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
22. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic curve. Radiology 1982;143:29-36.
23. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H, Palacios IF. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000;102:2966-72.
24. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implication of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36:1542-8.
25. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors and relationship to mortality. Am J Med 1997;103:368-75.
26. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002;90:1068-73.
27. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-64.
28. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39:1113-9.
29. Liu JY, Birkmeyer NJ, Sanders JH, et al. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. The Northern New England Cardiovascular Disease Study Group. Circulation 2000;102:2973-7.
30. Chertow GM, Levy EM, Hammermeister KE, et al. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998;104:343-8.
31. Mangano CM, Diamondstone LS, Ramsay JG, et al. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes and hospital resource utilization: the Multi-center Study of Perioperative Ischemia Research Group. Ann Intern Med 1998;128:194-203.
32. Eagle KA, Guyton RA, Davidoff R, et al. The American College of Cardiology/American Heart Association guidelines for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 1999;34:1262-347.
33. Sloand JA, Sloland EM. Studies on platelet membrane glycoproteins and platelet function during hemodialysis. J Am Soc Nephrol 1997;8:799-803.
34. Komarnicki M, Kazmierczak M, de Mezer-Dembek M. Binding of monoclonal antibodies to platelet glycoproteins Ib and IIb/IIIa in uremic patients. Nephron 1997;75:283-5.
35. Sreedhara R, Itagaki I, Hakim RM. Uremic patients have decreased shear-induced aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 1996;27:355-64.
36. Gawaz MP, Dobos G, Spath M, Schollmeyer P, Gurland HJ, Mujais SK. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994;5:36-46.
37. Umemura K, Kondo K, Ikeda Y, Nakashima M. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban. Thromb Haemost 1997;78:1384-9.
38. Alton KB, Kosoglou T, Baker S, Affrime MB, Cayen MN, Patrick JE. Disposition of 14C-eptifibatide after intravenous administration to healthy men. Clin Ther 1998;20:307-23.
39. Ro 44-9883 (lamifiban) platelet aggregation inhibitor. Investigational Drug Brochure. F. Hoffman-La Roche, 1997.
40. Abciximab. Prescribing information. Eli Lilly Company.
41. Goa KL, Noble S. Eptifibatide. Drugs 1999 57:439-62.
42. McClellan KJ, Goa KL. Tirofiban. Drugs 1998;56:1067-80.
43. Platelet Receptor inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
44. Platelet Receptor inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
45. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
46. Lehne G, Nordal KP, Midtvedt K, Goggin T, Brosstad F. Increased potency and decreased elimination of lamifiban, a GP IIb-IIIa antagonist, in patients with severe renal dysfunction. Thromb Haemost 1998;79:1119-25.
47. Reddan DN, O'Shea JC, Williams K, et al. Treatment effect at different levels of creatinine clearance following eptifibatide in planned coronary stent implantation (abstr). J Am Coll Cardiol 2001;37 Suppl A:11A.
48. Januzzi JL, Snapinn SM, DiBattiste PM, et al. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency. Circulation 2002;105:2361-6.
49. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999;10:1606-15.
50. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocystine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
51. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000;83:205-9.
52. Sechi LA, Zingaro L, Catena C, Perin A, De Marchi S, Bartoli E. Liproprotein (a) and apoprotein (a) isoforms and proteinuria in patients with moderate renal failure. Kidney Int 1999;56:1049-57.
53. Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000;11:105-15.
54. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-911.